Charles Schwab Investment Management Inc. Sells 22,791 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO)

Charles Schwab Investment Management Inc. reduced its holdings in shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) by 2.4% in the 4th quarter, Holdings Channel.com reports. The fund owned 925,660 shares of the company’s stock after selling 22,791 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Organogenesis were worth $2,962,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ORGO. Assenagon Asset Management S.A. increased its stake in Organogenesis by 54.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 2,950,849 shares of the company’s stock valued at $9,443,000 after buying an additional 1,035,120 shares during the last quarter. State Street Corp boosted its stake in shares of Organogenesis by 0.6% during the 3rd quarter. State Street Corp now owns 1,459,767 shares of the company’s stock worth $4,175,000 after buying an additional 9,090 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Organogenesis by 35.5% in the 4th quarter. Bank of New York Mellon Corp now owns 418,820 shares of the company’s stock valued at $1,340,000 after acquiring an additional 109,762 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Organogenesis by 8.0% in the third quarter. Wellington Management Group LLP now owns 241,648 shares of the company’s stock valued at $691,000 after acquiring an additional 17,842 shares during the last quarter. Finally, JPMorgan Chase & Co. increased its position in shares of Organogenesis by 107.8% in the third quarter. JPMorgan Chase & Co. now owns 205,943 shares of the company’s stock valued at $589,000 after acquiring an additional 106,823 shares during the last quarter. 49.57% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Morgan Stanley boosted their price target on Organogenesis from $4.00 to $6.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 5th.

Insider Activity at Organogenesis

In related news, Director Michael Joseph Driscoll sold 25,000 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $5.10, for a total value of $127,500.00. Following the sale, the director now owns 166,879 shares in the company, valued at approximately $851,082.90. This represents a 13.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 36.90% of the stock is currently owned by company insiders.

Organogenesis Stock Performance

Shares of ORGO stock opened at $4.67 on Friday. The stock has a market cap of $592.29 million, a P/E ratio of -77.83 and a beta of 1.66. The company has a fifty day moving average price of $4.19 and a two-hundred day moving average price of $3.56. Organogenesis Holdings Inc. has a one year low of $2.17 and a one year high of $6.71. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.09 and a quick ratio of 2.74.

Organogenesis Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.